No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 20, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 20, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 20, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 17, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 16, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 15, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

April 15, 2019 dna 0
Related Articles

Direct-to-Consumer Genetic Testing’s Red Herring: “Genetic Ancestry” and Personalized Medicine.

Front Med (Lausanne). 2019;6:48

Authors: Blell M, Hunter MA

Abstract
The growth in the direct-to-consumer genetic testing industry poses a number of challenges for healthcare practice, among a number of other areas of concern. Several companies providing this service send their customers reports including information variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and genetic ancestry. In this article, we argue that such information should not be used in healthcare consultations or to assess health risks. Far from representing a move toward personalized medicine, use of this information poses risks both to patients as individuals and to racialized ethnic groups because of the way it misrepresents human genetic diversity.

PMID: 30984759 [PubMed]

No Image

Directed to consumer genetic testing. Perspective from the Ethics commission of the Spanish Society for Human Genetics.

April 1, 2019 dna 0
Related Articles

Directed to consumer genetic testing. Perspective from the Ethics commission of the Spanish Society for Human Genetics.

Med Clin (Barc). 2019 Mar 18;:

Authors: Pàmpols Ros T, García Sagredo JM, Pérez Aytés A, Díaz de Bustamante A

PMID: 30898448 [PubMed – as supplied by publisher]

No Image

Recent developments in genetic/genomic medicine.

March 22, 2019 dna 0
Related Articles

Recent developments in genetic/genomic medicine.

Clin Sci (Lond). 2019 Mar 15;133(5):697-708

Authors: Horton RH, Lucassen AM

Abstract
Advances in genetic technology are having a major impact in the clinic, and mean that many perceptions of the role and scope of genetic testing are having to change. Genomic testing brings with it a greater opportunity for diagnosis, or predictions of future diagnoses, but also an increased chance of uncertain or unexpected findings, many of which may have impacts for multiple members of a person’s family. In the past, genetic testing was rarely able to provide rapid results, but the increasing speed and availability of genomic testing is changing this, meaning that genomic information is increasingly influencing decisions around patient care in the acute inpatient setting. The landscape of treatment options for genetic conditions is shifting, which has evolving implications for clinical discussions around previously untreatable disorders. Furthermore, the point of access to testing is changing with increasing provision direct to the consumer outside the formal healthcare setting. This review outlines the ways in which genetic medicine is developing in light of technological advances.

PMID: 30837331 [PubMed – in process]